AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look ...

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double- ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...